| ||
Drug policy likely to catch new combination medicines in price net Hindu Business Line But the National Pharmaceutical Pricing Policy (NPPP), to be notified by the Government any day now, is set to take a cautious view on new combination drugs – that combine two or more medicines into a single pill. The NPPP is believed to have mandated ... See all stories on this topic » | ||
Pharmaceutical groups sue Alameda County over drug take-back program Monterey County Herald Big Pharma and its generic brethren teamed up in a lawsuit against Alameda County over the nation's first drug take-back program, which would make manufacturers responsible for leftover pharmaceuticals and the cost of their disposal. The lawsuit filed ... See all stories on this topic » | ||
| ||
TAKEDA PHARMACEUTICAL COMPANY LIMITED : Once a Week Oral ... 4-traders Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported data from a phase 1 / 2 study of once a week investigational MLN9708 in combination with standard dose ... See all stories on this topic » | ||
| ||
| ||
Feeling better versus getting better Appeal-Democrat The other day I was watching TV and one of those pharmaceutical ads came on — you know, the one where they show people frolicking through a meadow one moment, playing basketball and then dancing the next. All the while in the background you hear ... See all stories on this topic » | ||
Claris Lifesciences to form JV with Otsuka and Mitsui Equity Bulls The Board of Directors of Claris Lifesciences Ltd at its meeting held on December 07, 2012 has granted approval to the Company for entering into definitive agreements for a Joint Venture (Claris-Otsuka) with Otsuka Pharmaceutical Factory, Inc. (OPF ... See all stories on this topic » | ||
AcelRx Pharma announces pricing of public offering of common stock Healthcare Global AcelRx Pharmaceuticals, Inc announced the pricing of its previously underwritten public offering of 12,500,000 shares of its common stock, offered at a price of $3.33 a share to the public. The gross proceeds to AcelRx from this offering are expected ... See all stories on this topic » | ||
New Sub-Analyses Report Pradaxa® (dabigatran etexilate mesylate) May Be ... Sacramento Bee 8, 2012 -- /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from two new post-hoc sub-analyses comparing the clinical management and outcomes of patients who experienced major bleeding while treated with ... See all stories on this topic » |
This once a day Google Alert is brought to you by Google.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment